Oncology

  • Research Faculty

  • Show All

    Division Head

    A photo of Dr. Perentesis.

    John P. Perentesis, MD, FAAP Director, Division of Oncology and Cancer Programs

    is a nationally recognized expert in the development of new therapies for pediatric cancers, leading new clinical trials through the Children’s Oncology Group, the NCI Phase I/Pilot Consortium, and the Department of Defense-funded Neurofibromatosis Consortium. His laboratory focuses on leukemia/lymphoma pharmacogenetics and has developed novel anticancer drugs and discovered genes important in the growth of normal and malignant cells.

    513-636-8241
    john.perentesis@cchmc.org

    John P. Perentesis, MD, FAAP

    Director, Division of Oncology and Cancer Programs

    Deb Kleisinger Endowed Chair of Novel Cancer Treatments

    Executive Co-Director, Cancer and Blood Diseases Institute

    Director, Leukemia / Lymphoma Program

    Cincinnati Children's Principal Investigator, Children’s Oncology Group (COG)

    Cincinnati Children's Principal Investigator, National Cancer Institute Pediatric Phase 1 Consortium

    Academic Information

    Professor, UC Department of Pediatrics

    Phone: 513-636-8241

    Fax: 513-636-3549

    Email: john.perentesis@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Acute myeloid leukemia; neuroblastoma; PNET / Ewing's sarcoma and osteosarcoma; new anticancer drug development; Phase I clinical trials

    Research Interests

    Molecular etiology and pharmacogenetics of pediatric cancers; Down syndrome-associated leukemia; new anticancer drug development

    Biography

    John P. Perentesis, MD, is a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. His laboratory has developed novel anticancer drugs, and discovered genes important in the growth of normal and malignant cells. His laboratory is also developing the use of tumor and patients genetics research for personalizing therapies. In clinical research, he serves in leadership roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI Pediatric Phase I Consortium.

    In 2010, Dr. Perentesis was elected by pediatric oncologists from across the country to the national Executive Committee for the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest, cooperative children's cancer research entity. He also is in leadership efforts in the COG for new therapies for leukemia, and adolescent and young adult cancers.

    Education and Training

    MD: University of Michigan, Ann Arbor, MI, 1980.

    Residency: University of Minnesota Medical School, Minneapolis, MN, 1983.

    Fellowship: University of Minnesota Medical School, Minneapolis, MN, 1986.

    Postdoctoral: University of Minnesota Medical School, Minneapolis, MN, 1986.

    Certification: Pediatrics, 1989; Hematology/Oncology, 1990.

    Publications

    View PubMed Publications

    Grants

    The Children's Oncology Group Chair Grant. Site Principal Investigator. National Institutes of Health. Mar 2008 - Mar 2013. #U10 CA 098543.

    Children's Oncology Group Phase I. Site Principal Investigator. National Institutes of Health. Aug 2002 - Jul 2012. #U01 CA 097452.

    Children's Oncology Group New Publication Committee. National Institutes of Health. Sep 2006 - Jul 2012. #U01 CA 97542 .

    Cincinnati Children's Hyundai Scholar in Childhood Cancer Drug Development. Hyundai Hope on Wheels. Oct 2010 - Oct 2011.

    Faculty

    A photo of Michael Absalon.

    Michael J. Absalon, MD, PhD

    focuses on developing new therapies and combinations of therapies for pediatric leukemias and lymphomas. He is currently investigating the therapeutic potential of combining the new targeted drug sorafenib with conventional chemotherapy for relapsed AML.

    513-636-4266
    michael.absalon@cchmc.org

    Michael J. Absalon, MD, PhD

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-3549

    Email: michael.absalon@cchmc.org

    Show All

    Specialties

    Relapsed leukemia; lymphoma; new therapeutics; ataxia telangiectasia; DNA damage response mechanisms

    Education and Training

    BS: Lewis and Clark College, Portland, OR, 1987.

    PhD: Massachusetts Institute of Technology, Cambridge, MA, 1994.

    MD: Oregon Health Sciences University, Portland, OR, 1998.

    Fellowship: St. Jude Children's Research Hospital, Memphis, TN, 2005.

    Publications

    View PubMed Publications
    A photo of Denise Adams.

    Denise M. Adams, MD Marjory J. Johnson Chair of Vascular Tumor Translational Research

    is a nationally recognized expert on vascular anomalies with a keen interest in rare vascular tumors and life threatening malformations. She leads a clinical and translational research program to develop new therapies for these conditions and currently is the PI of a clinical study of sirolimus, a mTOR inhibitor, in the treatment of complicated vascular anomalies, the first trial of a new therapy for these conditions.

    513-636-4266
    denise.adams@cchmc.org

    Denise M. Adams, MD

    Marjory J. Johnson Chair of Vascular Tumor Translational Research

    Medical Director, Comprehensive Hemangioma and Vascular Malformation Center

    Fellowship Director, Hematology / Oncology

    Academic Information

    Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-3549

    Email: denise.adams@cchmc.org

    Show All

    Biography

    Dr. Denise Adams is the medical director of the Hemangioma and Vascular Malformations Center. She is one of the medical physicians who evaluate patients to identify the proper diagnosis and develop with families an optimal treatment plan. She is trained in hematology/oncology. Dr. Adams obtained her schooling from Georgetown University. She first came to Cincinnati Children’s in 2003, and has strived since that time to provide exemplary care for the children served here within our multidisciplinary team. One of the vascular team’s main priorities has been establishing standards of care for patients with these diagnoses so they can follow outcome measures. Of key interest to Dr. Adams, is the improving of the care of patients with kaposiform hemangioendotheliomas (KHE) and other rare vascular tumors. Dr. Adams was awarded the Marjory J. Johnson Chair of Vascular Tumor Translational Research for her impact and leadership in the advancement of knowledge of vascular anomalies and the transformation of care for her patients. Dr. Adams has led one of the first prospective NIH-funded trials for the treatment of complicated vascular anomalies; further studies are in development. Clinical trial summaries can be seen on www.ClinicalTrial.gov.

    Education and Training

    MD: Georgetown University School of Medicine, 1988.

    Post-Graduate: Georgetown University, 1983.

    BSN: Georgetown University, 1982.

    Publications

    View PubMed Publications
    A photo of Karen Burns.

    Karen C. Burns, MD, MS Director, Cancer Survivorship Center

    conducts research on cancer survivorship and serious late effects of cancer treatment, including obesity, heart problems, fertility issues, increased risk of second cancers, and long-term outcomes of cancer survivors. She is also leading development of a fertility preservation program for children and adolescents undergoing chemotherapy as well as other unique medical and support services for adolescent and young adult cancer patients.

    513-636-4266
    karen.burns@cchmc.org

    Karen C. Burns, MD, MS

    Director, Cancer Survivorship Center

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-3549

    Email: karen.burns@cchmc.org

    Show All

    Education and Training

    BA: University of Pennsylvania, Philadelphia, PA, 1995.

    MD: Temple University, Philadelphia, PA, 1999.

    Residency: Pediatrics, St. Christopher's Hospital for Children in Philadelphia, PA, 2002.

    MS: Medical College of Wisconsin, 2005.

    Fellowship: Medical College of Wisconsin, 2005.

    Publications

    View PubMed Publications
    A photo of Lionel Chow.

    Lionel M. L. Chow, MD, PhD St. Baldrick’s Foundation Scholar

    studies high-grade gliomas, which are aggressive brain tumors in adults and children with limited treatment options. Using a combination of novel and robust laboratory models coupled with the study of human tumor material, the lab’s goals are to better understand the cellular origins and molecular underpinnings of these diseases in order to design and test novel therapies that will hopefully improve patient outcome.
    Visit the Chow Lab

    513-803-1369
    lionel.chow@cchmc.org

    Lionel M. L. Chow, MD, PhD

    St. Baldrick’s Foundation Scholar

    Sontag Foundation Distinguished Scientist

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-803-1369

    Fax: 513-803-1083

    Email: lionel.chow@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Pediatric neuro-oncology

    Research Interests

    Mouse models for glioma; molecular profiling of tumor mutations; biomarkers of tumor progression; novel therapeutic agents for glioma

    Visit the Chow Lab

    Biography

    Lionel Chow, MD, PhD, received his medical and graduate degrees from McGill University in Montreal, Canada, where his research focused on the regulation of T-lymphocyte signaling by the intracellular tyrosine protein kinases Lck and Csk.

    Following his clinical training in pediatrics and pediatric hematology / oncology at the Hospital for Sick Children in Toronto, Canada, he moved to St. Jude Children’s Research Hospital in Memphis, Tenn., to pursue his research interests.

    Chow's research interests have been centered on glioblastoma multiforme, a particularly devastating form of cancer in adults and children. His work has resulted in the development of a number of novel and robust laboratory models for this disease. Using these models and interfacing with clinical trials in the Neuro-Oncology Program as well as those from national consortia such as the Children's Oncology Group (COG) and the Pediatric Brain Tumor Consortium (PBTC), Chow’s laboratory will continue research in this area with the goals of better understanding the origins of this form of cancer and improving patient outcomes.

    Education and Training

    PhD: McGill University, Montreal, Quebec, Canada, 1996.

    MDCM: McGill University, Montreal, Quebec, Canada, 1997.

    Residency: The Hospital for Sick Children, University of Toronto, Toronto, Canada, 1997-2000.

    Clinical Fellowship: The Hospital for Sick Children, University of Toronto, Toronto, Canada, 2000-2003.

    Postdoctoral Fellowship: St. Jude Children’s Research Hospital, Memphis, TN, 2003-2009.

    Clinical Fellowship: St. Jude Children’s Research Hospital, Memphis TN, 2008-2009.

    Certification: Pediatrics, 2000.

    Publications

    View PubMed Publications

    Grants

    2013 – 2014 Sophie’s Angel Run Foundation
    “Preclinical Testing of Notch and mTor Inhibition in a Mouse Model for High-Grade Glioma” 

    2011 – 2014 St. Baldrick’s Foundation Scholars Award
    "Molecular targeting of pediatric high-grade glioma"

    2011 – 2015 Sontag Foundation Distinguished Scientist Award
    "Molecular targeting of high-grade astrocytoma"

    A photo of Dr. Biplab Dasgupta.

    Biplab Dasgupta, PhD, MS

    focuses on the integration of metabolic and signaling pathways in neural cells including neural and brain cancer stem cells. He is particularly interested in understanding the link between cellular energy sensing pathways with cellular signaling circuits that are controlled by growth factors and their receptors. Mouse models are used to understand the development of high grade human and mouse brain tumor (glioma).
    Visit the Dasgupta Lab.

    513-803-1370
    biplab.dasgupta@cchmc.org

    Biplab Dasgupta, PhD, MS

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-803-1370

    Fax: 513-803-1083

    Email: biplab.dasgupta@cchmc.org

    Show All

    Specialties

    Biography

    Biplab Dasgupta, PhD, MS, completed his doctorate in molecular biology and immunology at the Indian Institute of Chemical Biology, Calcutta, and a postdoctoral fellowship at Washington University School of Medicine, Saint Louis. Dr. Dasgupta came to Cincinnati Children's Hospital Medical Center in August 2009 as an assistant professor of pediatrics. He is interested in understanding how neural cell / stem cell metabolic and energy status is linked to cell cycle, lineage commitment, differentiation and tumorigenesis. His other interests include genetic, developmental, post-translational, tissue- and stimuli–specific regulation of the subunits that constitute the AMP kinase complex.

    Education and Training

    PhD: Indian Institute of Chemical Biology, Calcutta, 2003

    Postdoctoral Fellowship:
    Washington University School of Medicine, Saint Louis

    Publications

    View PubMed Publications

    Grants

    Regulation of Forebrain Neurogenesis by the Energy Sensor AMP Kinase. Principal Investigator. National Institute of Neurological Disorders and Stroke (NINDS). July 2012 – June 2017.
    A photo of Rachid Drissi.

    Rachid Drissi, PhD

    studies replicative senescence or cellular aging, believed to be a tumor suppressor mechanism by which normal cells limit cell proliferation to prevent genome instability and cancer. The long-term goal of our research program is to examine telomere disruption signaling to DNA damage pathway and senescence. We are also developing a combination therapy that includes telomere disruption to improve the outcome for children with brain tumors. 

    513-636-4266
    rachid.drissi@cchmc.org

    Rachid Drissi, PhD

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-3549

    Email: rachid.drissi@cchmc.org

    Show All

    Education and Training

    BS: University of Rouen, France, 1983.

    MS: University of Rouen, France, 1984.

    MS: University of Paris VI, France, 1988.

    PhD: University of Paris VI, France, 1994.

    Publications

    View PubMed Publications
    A photo of Maryam Fouladi.

    Maryam Fouladi, MD, MSc, FRCPC Medical Director, Neuro-Oncology Program

    serves as chair for the CNS Tumor New Agents/Relapse Committee for the Children’s Oncology Group, and as member of the steering committee for the COG CNS Tumor Committee and the Collaborative Ependymoma Research Network (CERN). She serves as local and national study chair for active open clinical trials that test new approaches to treat children with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.

    513-636-4266
    maryam.fouladi@cchmc.org

    Maryam Fouladi, MD, MSc, FRCPC

    Medical Director, Neuro-Oncology Program

    Cincinnati Children's Principal Investigator, Collaborative Ependymoma Research Network

    Academic Information

    Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-3549

    Email: maryam.fouladi@cchmc.org

    Show All

    Biography

    Maryam Fouladi, MD, MSc, graduated from the University of Toronto School of Medicine, and completed her pediatric residency and hematology / oncology fellowship training at the Hospital for Sick Children in Toronto, Canada. Dr. Fouladi then completed her neuro-oncology fellowship training at St. Jude Children's Research Hospital, and later completed further training in the molecular pharmacology department at St. Jude before becoming a  neuro-oncology faculty member in 2000. She served as the chair of the Phase I Committee at St. Jude.

    Dr. Fouladi moved to Cincinnati Children's in 2008 to direct the neuro-oncology program. She is currently chair for the CNS Tumor New Agent Committee for the Children’s Oncology Group. She is a member of the steering committee for the COG CNS Tumor Committee as well as the Developmental Therapeutics group at COG, and is a member of the Collaborative Ependymoma Research Network (CERN). She serves as local and national study chair (through CERN, COG and the Pediatric Brain Tumor Consortium) for clinical trials that test new approaches to treat children with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.

    Education and Training

    BS: Human Biology, University of Toronto, Toronto, Canada, 1987. 

    MD: University of Toronto, Toronto, Canada, 1991.

    MSc: Institute of Medical Science, University of Toronto, Toronto, Canada, 2002.

    Publications

    View PubMed Publications
    A photo of James Geller.

    James I. Geller, MD Medical Director, Kidney and Liver Tumors Program

    focuses on children and young adults affected by solid tumors. Dr. Geller's expertise is recognized internationally, as witnessed by his appointments to the Children's Oncology Group (COG) Renal Tumor, Liver Tumor, Retinoblastoma and Central Nervous System (Brain Tumor) Committees. Dr. Geller directs and spearheads local and national studies in these areas, with an emphasis on novel therapeutics.

    513-636-4266
    james.geller@cchmc.org

    James I. Geller, MD

    Medical Director, Kidney and Liver Tumors Program

    Co-Medical Director, Retinoblastoma Program

    Associate Director, Global Cancer Programs

    Academic Information

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-3549

    Email: james.geller@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Developmental therapeutics; renal / liver / retinoblastoma / neuro-oncology

    Research Interests

    Elucidating ways to translate the use of biological response modifiers in combination with conventional chemotherapeutics

    Biography

    James I. Geller, MD, completed his undergraduate training at Dartmouth College, graduate medical training at the Sackler School of Medicine, residency training in pediatrics at New York Medical College and pediatric hematology / oncology training at St. Jude Children's Research Hospital. His current appointment is with the University of Cincinnati and Children's Hospital Medical Center in the capacity of associate professor of pediatrics.

    Dr. Geller's clinical and academic interests pertain to children and families affected by solid tumors, including brain tumors. Dr. Geller's expertise is recognized both nationally and internationally in the fields of retinoblastoma, renal tumors, liver tumors and brain tumors, as witnessed by his appointments to the Children's Oncology Group (COG) Rare/Retinoblastoma Committee as both a Steering/Voting Member and as liaison to the COG Young Investigator Committee; the COG Renal Tumor Committee (RTC) as Steering/Voting Member, RTC Sub-Committee Chair of Developmental Therapeutics, and RTC liaison to both the COG Developmental Therapeutics Committee and the Pediatric Preclinical Testing Program Guidance Committee; and to the Central Nervous System (Brain Tumor) Committee as a voting member. Dr. Geller has been an invited speaker at numerous national and international meetings and symposia and spearheads both local and national clinical research initiatives in these areas, with an emphasis on finding new treatment options.

    Education and Training

    MD: Sackler School of Medicine, 1997.

    Residency: New York Medical College, 2000.

    Fellowship: St Jude Children's Research Hospital, 2004.

    Certification: Pediatrics, 2000, 2007; Pediatric Hematology / Oncology, 2005.

    Publications

    View PubMed Publications
    A photo of Adrienne M. Hammill.

    Adrienne M. Hammill, MD, PhD

    conducts clinical research on hemangiomas and vascular malformations, focusing on development of new therapies for these conditions and new tools for assessing response to therapy, including novel imaging modalities. 

    513-636-0673
    adrienne.hammill@cchmc.org

    Adrienne M. Hammill, MD, PhD

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-636-0673

    Email: adrienne.hammill@cchmc.org

    Show All

    Specialties

    Hemangiomas and vascular malformations; genetic predispositions to cancer

    Biography

    Dr. Adrienne M. Hammill is trained in pediatrics and hematology/oncology and is particularly interested in bringing new and/ or better medical therapy options to the treatment of vascular anomalies. She is one of the medical physicians for the Hemangioma and Vascular Malformations team. She obtained her schooling at the University of Texas Southwestern, and completed her residency and fellowship here at Cincinnati Children’s Hospital Medical Center. She is a dedicated professional and strives to improve the treatment of those she cares for. Dr. Hammill has a special interest in Sturge Weber syndrome and due to her dedicated involvement, Cincinnati Children’s has been named a site for the brain vascular malformations consortium, which is a clinical research group funded by National Institutes of Health and the rare disease network. She was nominated as a finalist for The Making a Difference Award in 2013 through the Patient Advisory Council. This nomination for staff was for their efforts to improve the patient’s experience in terms of lives saved, errors caught, kindness shown, and battles fought. A Cincinnati Children’s patient nominated Dr. Adrienne Hammill for making her feel secure and talking to her one-on-one as a friend not a doctor.

    Education and Training

    MD: University of Texas Southwestern Medical School, Dallas, TX, 2004.

    PhD: University of Texas Southwestern Graduate School of Biomedical Sciences, Dallas, TX, 2004.

    Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

    Fellowship: Cincinnati Children’s Hospital Medical Center.

    Certification: Pediatrics, 2008.

    Publications

    View PubMed Publications
    A photo of Trent Hummel.

    Trent R. Hummel, MD

    focuses on developing novel therapeutics to treat children with all central nervous system tumors including those with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas. Dr. Hummel is leading a national Phase 1 clinical trial investigating temozolomide in combination with vorinostat.

    513-803-1126
    trent.hummel@cchmc.org

    Trent R. Hummel, MD

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-803-1126

    Fax: 513-636-3549

    Email: trent.hummel@cchmc.org

    Show All

    Specialties

    Neuro-oncology; CNS tumors in neurofibromatosis type 1 and 2 research interests: developing novel therapeutics in central nervous system tumors including those with very poor prognosis such as high grade gliomas and diffuse intrinsic pontine gliomas.

    Biography

    Trent R. Hummel, MD, completed his graduate medical training at the University of Cincinnati College of Medicine, residency training in pediatrics at Children's Hospital Medical Center of Akron and pediatric hematology/oncology training at Cincinnati Children's Hospital Medical Center. His current appointment is with the University of Cincinnati and Children's Hospital Medical Center in the capacity of assistant professor of pediatrics.

    Dr. Hummel's clinical and academic interests pertain to children and families affected by central nervous system tumors. He is a member of the Central Nervous System (Brain Tumor) Committee in the Children's Oncology Group (COG) as well as the Cincinnati Children's co-principal investigator for the Pediatric Brain Tumor Consortium (PBTC). Dr. Hummel focuses on developing novel therapeutics to treat children with all central nervous system tumors including those patients with neurofibromatosis type 1 and 2 related CNS tumors and very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.

    Education and Training

    BS: Eastern Mennonite University, 1997. 

    MD: University of Cincinnati College of Medicine, 2001.

    Residency: Children’s Hospital Medical Center of Akron, Akron, Ohio, 2004.

    Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, 2007; Research Fellow, Division of Experimental Hematology, Cincinnati Children’s Hospital Medical Center, 2008.

    Certification: American Board of Pediatrics, 2004; Pediatrics, 2004. Pediatric Hematology / Oncology, 2011.

    Publications

    View PubMed Publications
    A photo of Jennifer Mangino.

    Jennifer L. Mangino, MD

    has clinical and academic interests that pertain to children and young adults with leukemias and lymphomas, with a focus on clinical trials for patients with relapsed or refractory disease. She also has a special interest in adolescent and young adult oncology patients.

    513-803-5259
    jennifer.mangino2@cchmc.org

    Jennifer L. Mangino, MD

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-803-5259

    Email: jennifer.mangino2@cchmc.org

    Show All

    Specialties

    Clinical

    Leukemia; Lymphoma; adolescent and young adult oncology patients.

    Research

    Novel therapies for children with relapsed or refractory leukemia and lymphoma.

    Biography

    Dr. Mangino earned her undergraduate degree in biochemistry and her medical degree from The Ohio State University, completed her residency in pediatrics at Children’s Memorial Hospital in Chicago, and her fellowship in pediatric hematology/oncology at Children's Hospital of Philadelphia. She was awarded a National Cancer Center grant (2011-2013) for her post-fellowship research.

    Education and Training

    MD: The Ohio State University, Columbus, OH, 2004.

    Residency: Pediatrics, Children's Memorial Hospital, Chicago, IL, 2007.

    Fellowship: Children's Hospital of Philadelphia, Philadelphia, PA, 2011.

    Certification: Pediatrics, 2007; Pediatric Hematology and Oncology, 2013.

    Publications

    View PubMed Publications
    A photo of Benjamin Mizukawa, MD.

    Benjamin E. Mizukawa, MD

    is trained in pediatric hematology/oncology with a research emphasis in leukemia biology and novel therapeutics. His work is focused on understanding the role of small Rho GTPases in myeloid leukemia development and progression, with the translational goal of identifying new targets for drug development.

    513-636-1335
    benjamin.mizukawa@cchmc.org

    Benjamin E. Mizukawa, MD

    Academic Information

    Instructor, UC Department of Pediatrics

    Phone: 513-636-1335

    Email: benjamin.mizukawa@cchmc.org

    Show All

    Specialties

    Pediatric leukemia and lymphoma; investigation of the role of small Rho GTPases in leukemogenesis and leukemic stem cell biology and their potential as therapeutic targets in acute myeloid leukemia; development of xenograft models for use in testing novel therapeutics

    Education and Training

    MD: University of Utah, Salt Lake City, UT, 2004.

    Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

    Fellowship: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

    Certification: Pediatrics, 2008
    Pediatric Hematology/Oncology, 2011

    Publications

    View PubMed Publications

    Grants

    Characterization of Rho GTPases in acute myeloid leukemia (AML) and their potential as therapeutic targets. Principal Investigator. Pediatric Scientist Development Program (PSDP) Fellowship. 2008 - 2011.

    Targeting Leukemia Cell Interaction with the Marrow Niche. Sub-Investigator. Child Health Research Career Development Award (CHRCDA) NIH K12. 2011 - 2012.

    Targeting Cdc42 in Leukemia Stem Cells. Principal Investigator. Procter Scholar Award. Cincinnati Children's Hospital Research Foundation. 2012 - 2013.

    A photo of Rajaram Nagarajan, MD.

    Rajaram Nagarajan, MD, MS Associate Director, Oncology Clinical Operations

    focuses on quality of life and outcomes following cancer therapy. His large collaborative studies involve the Children’s Oncology Group (COG), the Children's Cancer Survivor Study (CCSS) and National Children’s Hospital and Related Institutions (NACHRI) initiative. Dr. Nagarajan co-directs the Long-Term Follow-up Program which follows over 1,400 survivors, a unique program that follows “children” who are now well into adulthood.

    513-636-0670
    rajaram.nagarajan@cchmc.org

    Rajaram Nagarajan, MD, MS

    Associate Director, Oncology Clinical Operations

    Academic Information

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-0670

    Fax: 513-636-3549

    Email: rajaram.nagarajan@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Bone tumors; late effects of pediatric cancer therapy

    Research Interests

    Outcomes following cancer therapy and bone sarcomas

    Education and Training

    BA: Pre-Medical Sciences, Lehigh University, Bethlehem, PA, 1991.

    MD: Medical College of Pennsylvania, Philadelphia, PA, 1995.

    Internship and Residency: Pediatrics, Medical College of Virginia, Richmond, VA, 1998.

    Fellowship Training: Hematology / Oncology / BMT, University of Minnesota, Minneapolis, MN, 2002.

    MS: Clinical Research, University of Minnesota, Minneapolis, MN, 2002.

    Certifications: Pediatrics, Pediatric Hematology / Oncology.

    Publications

    View PubMed Publications
    A photo of Maureen O'Brien.

    Maureen M. O'Brien, MD, MS Associate Director, Leukemia / Lymphoma Program

    is a clinical researcher developing new therapies for children, adolescents, and young adults with leukemia and lymphoma including combination of the mTOR inhibitor sirolimus with chemotherapy for patients with relapsed acute lymphoblastic leukemia. Her other research interests include improvements in the supportive care of patients with cancer, with a focus on identification of genetic risk factors and biomarkers for chemotherapy-related toxicity and infectious complications.

    513-803-1678
    maureen.obrien@cchmc.org

    Maureen M. O'Brien, MD, MS

    Associate Director, Leukemia / Lymphoma Program

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-803-1678

    Fax: 513-636-3549

    Email: maureen.obrien@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Leukemia; lymphoma

    Research Interests

    Molecular etiology of pediatric leukemias, especially in children with Down syndrome; novel therapeutics for relapsed and high-risk leukemia and lymphoma

    Education and Training

    MD: Harvard Medical School, Boston, MA, 2000.

    Residency: Boston Combined Residency Program, Boston Children's Hospital and Boston Medical Center, Boston, MA, 2003.

    Fellowship: Stanford University School of Medicine, Stanford, CA, 2007.

    MS: Stanford University, Stanford, CA, 2008.

    Certification: Pediatrics, 2003; Pediatric Hematology/Oncology, 2009.

    Publications

    View PubMed Publications
    A photo of Christine Phillips.

    Christine L. Phillips, MD

    is a clinical oncologist with a clinical and translational research focus on the development of novel therapies for pediatric leukemia and in leukemia pharmacogenetics. Recent work has involved examining common genetic polymorphisms and their contribution to efficacy of therapy and risk for side effects in patients with acute myeloid leukemia.

    513-803-1126
    christine.phillips@cchmc.org

    Christine L. Phillips, MD

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-803-1126

    Email: christine.phillips@cchmc.org

    Show All

    Specialties

    Leukemia and lymphoma; leukemia pharmacogenetics; translational and clinical development of new drugs for high-risk and relapsed leukemias

    Biography

    Christine Phillips, MD, is an oncologist with a clinical focus on leukemia and lymphoma and a clinical and translational research focus on the development of novel therapies for pediatric leukemia and in leukemia pharmacogenetics.

    Dr. Phillips earned her undergraduate degree in biochemistry and her medical degree from Indiana University, completed her residency in pediatrics at Children’s Memorial Hospital in Chicago, and her fellowship in pediatric hematology/oncology at Cincinnati Children’s, where she was co-chief fellow. She was a 2008 Hyundai Hope on Wheels Foundation Scholar.

    Education and Training

    MD: Indiana University School of Medicine, Indianapolis, IN, 2002.

    Residency:
    Pediatrics, Children’s Memorial Hospital, Chicago, IL, 2005.

    Fellowship:
    Pediatric Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, 2010.

    Certification: Pediatrics, 2005; Pediatric Hematology/Oncology, 2011.

    Publications

    View PubMed Publications
    A photo of Joseph Pressey.

    Joseph G. Pressey, MD Director, Musculoskeletal Tumor Program

    is the director of the musculoskeletal tumor program in the Cancer and Blood Diseases Institute.  His primary interests include the translational and clinical aspects of childhood and young adult sarcomas. Dr. Pressey’s research focuses on the identification of novel therapies for high risk and recurrent/refractory pediatric cancers and the conduct of early phase clinical trials.

    513-803-9083
    joseph.pressey@cchmc.org

    Joseph G. Pressey, MD

    Director, Musculoskeletal Tumor Program

    Program Leader, Young Adult Oncology Center

    Academic Information

    Associate Professor, UC Department of Pediatrics

    Phone: 513-803-9083

    Email: joseph.pressey@cchmc.org

    Show All

    Specialties

    Clinical

    Musculoskeletal tumors including rhabdomyosarcoma and other soft-tissue sarcomas; Ewing sarcoma; osteosarcoma; pediatric solid tumors; rare tumors including small cell carcinoma of the ovary.

    Research

    The development of novel therapies for pediatric sarcomas and rare tumors.

    Biography

    Dr. Pressey graduated from the University of Georgia and the Medical College of Georgia before pursuing pediatrics residency training at Cincinnati Children’s Hospital Medical Center. He trained in pediatric hematology-oncology at the Children’s Hospital of Philadelphia where he developed a keen interest in pediatric sarcomas. He spent 11 years at the University of Alabama at Birmingham School of Medicine and Children’s Hospital of Alabama where he functioned as the principal investigator (PI) for the Children’s Oncology Group (COG) phase 1 and Pilot Consortium and the Sarcoma Alliance for Research through Collaboration (SARC).

    Dr. Pressey joined the Cancer and Blood Diseases Institute at Cincinnati Children’s to direct the musculoskeletal tumor program. He is appointed clinical associate professor at the University of Cincinnati School of Medicine and functions as the Cincinnati Children’s Institutional PI for SARC. Dr. Pressey’s research is focused on the development of novel therapies for high-risk and recurrent/refractory solid tumors. Accordingly, he is developing a phase I trial for the COG phase I consortium and bench to bedside investigator initiated trials in collaboration with other investigators nationally.  

    Education and Training

    MD: Medical College of Georgia, Augusta, GA, 1995.

    Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1998.

    Fellowship: Pediatric Hematology-Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 2001.

    Certification: Pediatric Hematology-Oncology, 2002.

    Publications

    View PubMed Publications
    A photo of Susan Rose.

    Susan R. Rose, MD

    investigates hypothalamic pituitary function and disorders of growth, puberty or thyroid hormone. She has special interest in the effects of neural injury on hypothalamic-pituitary function, such as after traumatic brain injury, cranial radiation, anoxia, iron overload.

    513-636-4744
    susan.rose@cchmc.org

    Susan R. Rose, MD

    Academic Information

    Professor, UC Department of Pediatrics

    Phone: 513-636-4744

    Email: susan.rose@cchmc.org

    Show All

    Specialties

    Clinical

    Neuro-endocrinology; hypothalamic-pituitary injury; growth disorders; puberty disorders; thyroid disorders; late effects of cancer

    Research

    Hypothalamic-pituitary function

    Biography

    Susan Rose is professor in the Division of Endocrinology at Cincinnati Children’s Hospital Medical Center and the University of Cincinnati. She has published over 100 review articles or chapters, and about 100 peer-reviewed articles. These include updating guidelines for care of congenital hypothyroidism and writing the chapter on thyroid for Fanaroff's and Avery's textbooks of neonatology. She’s served on the state newborn screening (NBS) committee in Tennessee. She is involved in long term follow up of newborn screening for CAH and congenital hypothyroidism with Region 4 and with the Federal Workgroup on NBS Standards.

    She has clinical expertise and research interests in hypothalamic pituitary function, thyroid hormone disorders, and in disorders of growth or puberty. She has a special interest in the effects of central nervous system injury on hypothalamic-pituitary function. In addition, she has expertise and experience in evaluating the endocrine conditions associated with congenital bone marrow failure syndromes such as Fanconi anemia, Blackfan Diamond anemia, and Shwachman-Diamond syndrome. In addition, she is evaluating the endocrine consequences of hypothalamic-pituitary injury, including traumatic brain injury and injury from treatments for cancer, as well as comparing the relative efficacy of several treatments for precocious puberty. In this study, she will be developing growth curves specific to Fanconi Anemia, recognizing that healthy children with FA may not grow along the typical growth pattern of other healthy children.

    Education and Training

    MD: Case Western Reserve School of Medicine, 1980.

    MEd: School Psychology, University of Dayton, 1972.

    Residency: The Cleveland Clinic, 1983.

    Fellowship: National Institutes of Health, 1986.

    Certification: Pediatrics, 1985; Pediatric Endocrinology, 1986.

    Publications

    View PubMed Publications
    A photo of William Seibel.

    William L. Seibel, PhD

    is a synthetic medicinal chemist with over 20 years of industrial and academic experience in the discovery of biologically active molecules and optimization toward human clinical trials. His lab provides advice in lead discovery, hit-to-lead and lead optimization approaches, including medicinal chemistry, computational chemistry and screening.

    513-803-4870
    william.seibel@cchmc.org

    William L. Seibel, PhD

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-803-4870

    Email: william.seibel@cchmc.org

    Show All

    Specialties

    Small molecule drug discovery

    Biography

    William Seibel, PhD, completed his doctorate in chemistry at Harvard University.  He then worked for 19 years in various positions at Procter & Gamble Pharmaceuticals, managing migraine and antimicrobials drug discovery groups as well as technology groups in computational, modeling, structural biology and combinatorial chemistry.  He then served as head of the University of Cincinnati College of Medicine’s Compound Library and Cheminformatics group and as project manager for the Drug Discovery Center, both of which continue through his Cincinnati Children's Hospital Medical Center appointment. His interests are in working with various collaborators to find the most efficient and effective approaches to identify biologically active small molecules, and advance these leads to clinical candidate status.

    Education and Training

    PhD: Harvard University, Cambridge, MA, 1987.

    Publications

    View PubMed Publications
    A photo of Brian Turpin.

    Brian K. Turpin, DO

    Academic Information

    Instructor, UC Department of Pediatrics

    Phone: 513-636-4266

    Email: brian.turpin@cchmc.org

    Show All

    Biography

    Brian K. Turpin, DO, completed his undergraduate training at the University of Missouri, graduate medical training at the Kansas City University of Medicine and Biosciences, and pediatric residency and hematology / oncology fellowship at Cincinnati Children’s Hospital Medical Center where he served as co-chief fellow. 

    Dr. Turpin’s clinical and academic interests pertain to children and young adults with solid tumors, particularly sarcomas and neuroblastomas, with a research focus on the development of new drugs and clinical trials for patients with relapsed cancer.

    Education and Training

    DO: Kansas City University of Medicine and Biosciences.

    Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center.

    Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cancer and Blood Diseases Institute.

    Publications

    View Dr. Turpin's PubMed Publications
    A photo of Brian Weiss.

    Brian D. Weiss, MD Associate Director for Safety and Compliance, Cancer and Blood Diseases Institute

    focuses on new approaches to treat high-risk Neuroblastoma, including novel ways to use 131I-MIBG therapy, and on targeted agents for neurofibromatosis type 1-related tumors and malignancies. In addition, he is researching methods and processes to ensure error-free delivery of therapy. 

    513-636-9863
    brian.weiss@cchmc.org

    Brian D. Weiss, MD

    Associate Director for Safety and Compliance, Cancer and Blood Diseases Institute

    Cincinnati Children's Principal Investigator, New Approaches to Neuroblastoma Therapy Consortium

    Medical Director, Neuroblastoma Program

    Academic Information

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-9863

    Fax: 513-636-3549

    Email: brian.weiss@cchmc.org

    Show All

    Specialties

    Targeted agents for neurofibromatosis type 1-related malignancies; high-risk neuroblastoma and 131I-MIBG treatment of neuroblastoma; new approaches to targeting and killing neuroblastoma cells

    Education and Training

    MD: Northwestern University Medical School, Chicago, IL, 1993.

    Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997.

    Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000.

    Certification: National Medical Board; Pediatrics;1996, 2002; Pediatric Hematology-Oncology, 2000, 2007

    Publications

    View PubMed Publications

    Grants

    Children's Oncology Group Chairs Grant. National Institutes of Health (Children's Oncology Group)
    U10 CA 098543 Mar 2011 - Feb 2012.
    A photo of Susanne Wells.

    Susanne Wells, PhD Director, Epithelial Carcinogenesis and Stem Cell Program

    focuses on new targets of the HPV E6/E7 oncogenes, and characterizing these as potential risk factors for HPV infection and transformation. Research approaches include bioinformatics; analyses of primary, transformed and 3D cell culture systems; and mouse tumor models to facilitate translational endeavors. 
    Visit the Wells Lab.

    513-636-5986
    susanne.wells@cchmc.org

    Susanne Wells, PhD

    Director, Epithelial Carcinogenesis and Stem Cell Program

    Director, Postdoctoral Office

    Academic Information

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-5986

    Fax: 513-636-3549

    Email: susanne.wells@cchmc.org

    Show All

    Specialties

    Squamous cell carcinoma; mechanisms by which the HPV oncogenes subvert the host cell machinery to promote abnormal cell growth and cancer; role of specific cellular HPV targets in viral replication and cellular transformation

    Visit the Wells Lab.

    Biography

    Susanne Wells graduated from the University of Konstanz, Germany, with a degree in Biology. She completed her PhD in Molecular Biology at the State University of Stony Brook, NY, and her Postdoctoral Fellowship at Harvard Medical School, MA. Dr. Wells moved to Cincinnati Children's Hospital Medical Center in 2002 to study human papillomavirus infection and associated carcinogenesis.

    Education and Training

    BS: Biology, University of Konstanz, Germany, 1992.

    PhD: Molecular Genetics, State University of Stony Brook, NY, 1997.

    Postdoctoral Fellowship: Molecular Virology, Harvard Medical School, Boston, MA.

    Publications

    View PubMed Publications

    Grants

    Research Innovation Fund Award
    Title:
    Identification of FA disease biomarkers using NMR-based metabonomics
    PI: Susanne Wells
    Project Period: 2013-2014
    Funding by: Cincinnati Children's Hospital Medical Center


    2R01 CA116316
    Title:
    Role and regulation of the human DEK proto-oncogene
    PI: Susanne Wells
    Project Period: 2012 – 2017
    Funding by: National Institutes of Health

    DOD Idea Award
    Title:
    Targeting the Ron-DEK signaling axis in breast cancer
    PI: Susanne Wells and Susan Waltz
    Project Period: 2012 – 2014
    Funding by: Department of Defense

    2R01 CA102357
    Title:
    Fanconi Anemia and HPV transformation
    PI: Susanne Wells
    Project Period: 2009 – 2014
    Funding by: National Institutes of Health

    A photo of Jordan Wright.

    Jordan M. Wright, MD

    is a clinical instructor in pediatric hematology/oncology whose translational research focuses on pharmacogenomics of sirolimus.

    513-803-1687
    jordan.wright@cchmc.org

    Jordan M. Wright, MD

    Academic Information

    Instructor, UC Department of Pediatrics

    Phone: 513-803-1687

    Email: jordan.wright@cchmc.org

    Show All

    Specialties

    Clinical

    Pediatric hematology/oncology.

    Research

    Pharmacogenomics; bioinformatics.

    Education and Training

    MD: Medical College of Georgia, Augusta, GA, 2007.

    Residency: Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 2010.

    Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2013.

    Publications